World Health Organization Issues Warning Over Severe Lack of Obesity Jabs
Less than a tenth of individuals that would benefit from obesity jabs like Wegovy are able to get them, states the global health agency as it publishes its initial advice on the medications.
Considering more than one billion individuals worldwide now obese, it is advocating for broader and more equitable access to GLP-1 medication.
According to estimates, in excess of 2,000,000,000 are projected to be obese by 2030 unless action is taken.
"Our latest guidelines affirms that obesity is a lifelong illness that can be managed with comprehensive and ongoing treatment," said the agency's head Tedros Adhanom Ghebreyesus.
Significant expense, limited production capacity, and supply-chain constraints are key barriers to universal availability to the injections that can assist patients in reducing considerable body mass, explains the organization.
Skinny Jab Supply Crisis
Even in the present most optimistic case, the supply of such drugs might only reach approximately 100 million people – under 10% of those who need them, per the WHO.
The guideline calls on countries and companies to expand availability, via measures including patent sharing.
A patent on semaglutide – the core ingredient of Novo Nordisk's Wegovy – is scheduled to end in several nations in 2026.
How Obesity Injections Work
GLP-1 drugs imitate a body's own hormone to delay gastric emptying, curb appetite and increase satiety so people reduce food intake.
Individuals typically see weight reduction after several weeks of commencing the once-weekly jabs.
Research indicates patients may see weight return a year later of stopping the drug, when their normal hunger return.
To be above a healthy weight raises your likelihood for experiencing medical conditions, including type 2 diabetes, cardiovascular issues, brain attack, and certain malignancies.
Obesity impacts people in all nations and was responsible for millions of fatalities worldwide in 2024, per the health agency.
